Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00281294
Status:
TERMINATED
Last Update Posted:
2008-08-05
First Post:
2006-01-20
Brief Title:
A Phase 2 Study to Evaluate the Safety Tolerability and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
Sponsor:
PDL BioPharma Inc
Organization:
Facet Biotech
Study Overview
Official Title:
A Phase 2 Study to Evaluate the Safety Tolerability and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
Status:
TERMINATED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated early because the first phase didnt meet the endpoint
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as determined by a 50 improvement of an American College of Rheumatology criteria ACR50 response at Week 14 Stage A of study
Detailed Description:
To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as determined by a 50 improvement of an American College of Rheumatology criteria ACR50 response at Week 14 Stage A of study
Stage B of this trial is Double blind
Stage B of this trial is Double blind
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None